Since the first report on induced pluripotent stem (iPS) cells in 2006, iPS cells have attracted great public attention and research interest. Like embryonic stem (ES) cells, iPS cells are capable to self-renew infinitely, and maintain the developmental potential to differentiate into any types of cells in the body. More importantly, derivation of iPS cells is independent of embryos, circumventing the ethic issue tightly bound with ES cells. Thus, iPS cells seem to be a promising cell source for regenerative medicine. In this review, we summarize the recent patents and progress in derivation of iPS cells.
INTRODUCTION
Pluripotent stem cells, such as embryonic stem (ES) cell, are able to differentiate into any cell type in the body and to self-renew unlimitedly. There is no doubt that pluripotent stem cells have enormous potential in both basic research and therapeutic applications, especially in developmental biology and regeneration medicine. The therapeutic value of ES cells has been demonstrated in a proof-principle experiment, wherein immune function was restored in immunedeficient Rag2 -/-mice by treatment of "repaired" ES cell derivatives [1] . We can envision the use of pluripotent stem cells or their derivatives to repair damaged tissues, such as those resulted from spinal cord injuries, acute myocardial infarctions, neurological disorders or Type 1 diabetes [2] .
I. EMBRYONIC STEM CELLS AND SOMATIC CELL REPROGRAMMING
The most extensively studied pluripotent stem cell is ES cells, which are derived from the inner cell mass of the blastocyst [3] [4] [5] . ES cells are able to differentiate into more than 200 types of cells, even to form a whole organism [6] . It appears that ES cells provide a perfect donor cell source for cell-replacement therapy. Their self-renewal property ensures unlimited supply of cells. Meanwhile, their pluripotency allows directed differentiation into desired cell type, which are then transplanted into patients to treat diseases. However, generation of human embryonic stem cells requires destruction of developing embryos, which obviously raises moral and ethical concerns. Moreover, when transplanted into patients, ES cells or their derivative cells could cause immunological rejection. In order to avoid ethical issues and immunological rejection, efforts were made to develop new methods to generate pluripotent stem cells as follows. At present, there are three approaches to derive pluripotent stem cells from somatic cells: nuclear transfer, cell fusion and transcription factor transduction [7] . In a nuclear transfer experiment, a nucleus from a differentiated somatic cell is transplanted into an enucleated oocyte to reprogram embryonic development. If transplanted into pseudopregnant mother, nuclear transferred embryos may develop into individual animals, which share identical genetic material with the original somatic cell. The birth of cloned sheep "Dolly" was the first prove-principle experiment for nuclear transfer [8] . Subsequently, therapeutic cloning was proposed to generate autologous ES cells [9] . In therapeutic cloning, nuclear transferred embryos are allowed to develop to the blastocyst stage in vitro. ES cells are then established from these blastocysts. When patient somatic cells are used as donor cell for nuclear transfer, the resultant ES cells should be histocompatible to the patient, solving the immune rejection problem. However, limited supply of human oocytes, low efficiency of ES cell derivation and ethical issues of destroying human blastocysts impede the application of therapeutic cloning in human patients.
Pluripotent stem cells can be established by fusion between somatic cells and ES cells. These fused cells could contribute to the three germ layers in chimeric embryos, indicating their pluripotency [10] . However, these pluripotent stem cells are tetraploid, restricting their applications in regenerative medicine and developmental biology research.
The most promising method to generate pluripotent cells from somatic cells is to ectopically express a combination of reprogramming factors in somatic cells. The resulting cells are called induced pluripotent stem (iPS) cells, which is described in details later.
II. ESTABLISHMENT OF iPS CELLS
Nuclear transfer and cell fusion experiments imply that ES cells and oocytes contain factors that can reprogram somatic cells and restore the developmental potential to the pluripotent state. Can we derive pluripotent stem cells by introducing these factors into somatic cells? Yamanaka and his colleagues test this hypothesis directly. Through analyzing gene expression profiles, they first identified 24 transcription factors highly expressed in early mouse embryos, ES cells, and embryonic carcinoma cells. These transcription factors were then retro-virally introduced into mouse embryo fibroblast (MEF) cells carrying neo gene driven by Fbx15 promoter (Fbx15 is a gene highly expressed in ES cells). After selection for Neo-resistance, morphologically ES-like colonies appeared. These ES-like cells were pluripotent: expressing pluripotency markers, supporting the formation of teratoma, and contributing to mouse embryonic development [11] . Since the pluripotency in these cells was induced by ectopic expression of reprogramming factors, these cells were named as induced pluripotent stem (iPS) cells. Moreover, through reducing transcription factors for iPS cell derivation, four transcription factors, Oct4, Sox2, Klf4 and c-Myc, were identified as key factors for converting MEF cells into iPS cells. These four transcription factors are called Yamanaka factors and widely used in later iPS cell derivation [11] . Immediately, Dr. Yamanaka and Kyoto University used a fast-track system to file a patent (JP2008131577) in Japan, and it was granted on September 2, 2008. This is the first issued patent on iPS cells. However, the first iPS cell patent outside Japan was granted to Kazuhiro Sakurada on January 12, 2010 [12] . Till now, there are numerous pending patents related to these two granted patents. The related pending patents have been summarized elsewhere [13] . The success in iPS cell derivation provides us an alternative type of pluripotent cells, other than ES cells. As for therapeutic applications, iPS cells have several advantages over ES cells. First, establishment of iPS cells does not require any oocytes or embryos, thus avoiding the ethic restriction. Second, with some somatic cells from patients themselves, such as skin fibroblasts, patient-specific iPS cells can be easily derived. These patient-specific iPS cells are autologous, and should not have the problem of immune rejection. Therefore, iPS cells hold great promise for regenerative medicine and cell-replacement therapy.
The success in mouse iPS cell derivation stimulated efforts to generate iPS cells of other species, especially human iPS cells. In 2007, several groups established human iPS cells, using similar approaches [14] [15] [16] [17] . It is noticeable that Yu et al. derived human iPS cells with a different combination of transcription factors, Oct4, Sox2, NANOG, and LIN28, while Yamanaka factors were used in most of these studies [15, 18] . Soon after that, rat, monkey, and pig iPS cells were also established [19] [20] [21] [22] [23] [24] . It proves that iPS technology is applicable to not only mouse, but also other mammals, including human. Moreover, iPS technology is so robust that it works in many independent laboratories all over the world.
III. IMPROVEMENT IN iPS CELL DERIVATION
Even though the technique of iPS cell derivation is robust and reproducible, there are many problems associated with iPS cells. Especially, safety issues impede clinical application of iPS cells, for example, tumor formation tendency of iPS cells and insertion mutations caused by viral vector integration. Before iPS cells can be applied in cell-replacement therapy, these safety issues should be resolved. Many new methods and strategies have been developed to improve iPS cell production and to promote therapeutic application of iPS cells.
Establishment of iPS Cells with Authentic Pluripotency
The first iPS cells, which were produced under Fbx15-neo selecting system were reported to lack capability to make chimeric mice, suggesting that they did not have authentic pluripotency [11] . It might be due to the Fbx15-Neo selection system. Fbx15 is not essential for pluripotency maintenance, despite its high expression level in ES cells. Thus, selection for critical pluripotency markers may benefit the pluripotency of iPS cells. Indeed, using Nanog or Oct4 reporter systems, better iPS cells were generated. The new iPS cells are able to generate chimeric mice efficiently. More importantly, these iPS cells contribute to germ cell development, and produce iPS cell progeny mice through germline transmission [25] [26] [27] . Furthermore, it has been demonstrated that entirely iPS cell-derived mice (all-iPS mice) can be born through tetraploid embryo complementation [28] [29] [30] . With more iPS cell lines established and more groups working on iPS cells, we started to understand the molecular mechanism of pluripotency in iPS cells. A new reprogramming factor Tbx3 has been shown to significantly improve the quality of iPS cells. iPS cells derived with Oct4, Sox2, Klf4 and Tbx3, have higher efficiency in both germ-cell contribution to the gonads and germ-line transmission [31] . The pluripotency of iPS cells is linked to the transcription status of the imprinted Dlk1-Dio3 gene cluster on chromosome 12qF1. Compared with ES cells, the Dlk1-Dio3 gene cluster was silenced in most of iPS cell clones. These iPS cell clones contributed poorly to chimeras and failed to generate all-iPS mice. In contrast, iPS cells with normal expression of the Dlk1-Dio3 cluster contributed to high-grade chimaeras and gave rise to viable all-iPS mice [32, 33] . It is just the beginning of understanding pluripotency in iPS cells; more investigations are needed to reveal the underlying mechanisms for somatic reprogramming and iPS cell pluripotency.
Derivation of iPS Cells From Genetically Unmodified Somatic Cells
The original method of iPS cell derivation used genetically modified donor somatic cells so that iPS cell clones could be selected by activation of drug-resistance genes. However, when it comes to clinical applications, genetic modifications should be avoided. First of all, genetic modification through homologous recombination is an inefficient and time-consuming process. Second, safety issues might arise when cells with genetic modifications are transplanted into patients. Moreover, the genetic modification step increases the cost for iPS cell derivation. Fortunately, iPS cells have distinct colony morphology than differentiated somatic cells. Thus, iPS cell colonies can be identified based on their ES-like colony morphology, after reprogramming somatic cells with Yamanaka factors [34, 35] . Another property of pluripotent cells also facilitates iPS cell identification after reprogramming. iPS cells, as well as ES cells, silence virally-expressed genes. If somatic cells are reprogrammed with viruses co-expressing GFP gene and Yamanaka factors, inactivation of GFP expression is an indicator for iPS colonies [36, 37] . In addition, iPS cells express ES-cell specific surface markers, such as TRA-1-60 and TRA-1-81 for human iPS cells. By live immunofluorescence staining of these surface markers, authentic iPS cell colonies can be identified [37] . Therefore, these properties of iPS cells allow iPS cell generation with unmodified somatic cells, and benefit easy production of human patient-specific iPS cells.
Reducing the Tumorigenicity of iPS Cells
Among the four Yamanaka factors for reprogramming somatic cells, c-Myc is a well-known oncogene, and Klf4 is also involved in many types of tumors [38, 39] . Do iPS cells have higher tendency to develop tumor due to these oncogenes? The answer is yes. Tumors were found in around 20% of iPS cell F1 progeny mice, mainly due to the reactivation of c-Myc [25] .
To reduce the tumorigenicity of iPS cells, at least four strategies have been tried. First, iPS cells were derived with Oct4, Sox2 and Klf4, without c-Myc. Omitting c-Myc drastically decreased the efficiency of iPS cell generation. Yet, the quality and pluripotency of iPS cells was not compromised. More importantly, the tumorigenicity of iPS cells was suppressed; no tumor was developed in iPS cell (without c-Myc) F1 progeny mice 100 days after birth [40, 41] . Alternatively, transforming-deficient Myc, L-Myc and Myc mutants (W136E and dN2), can replace c-Myc, not only improving reprogramming efficiency, but also decreasing tumor formation rate [42] . Second strategy is to remove the integrated exogenous genes after successful somatic reprogramming. Cre/LoxP system was applied to remove transgenes in established iPS cells. The resulted iPS cells are free of exogenous reprogramming factors [43] [44] [45] . However, a part of the vector backbone was left in the genomic DNA. Thus, the risk of insertion mutation does not change, while the tumorigenicity of iPS cells is reduced. piggyBac (PB) transposon system appears to be better than Cre/LoxP system. PB transposon can mediate the ectopic expression of reprogramming factors. After iPS cells were established with PB transposon, transient expression of transposase in these iPS cells leaded to seamless removal of exogenous genes [44, 46] . Third, iPS cells can be derived with non-integrating vectors and transient expression methods. These methods include: (1) Adenoviruses or Sendai viruses transiently expressing four Yamanaka factors [47, 48] , (2) Liposome-mediated transfection of non-viral expression vectors [49] , (3) Non-integrating episomal vectors to express reprogramming factors [50] [51] [52] , (4) Reprogramming proteins, instead of genes encoding these reprogramming factors [53] [54] [55] [56] . Comparisons among these methods were summarized in Table 1 . In the first three methods, reprogramming factors are transiently expressed from different non-integrating vectors to reprogram somatic cells. And these vectors diminished as iPS cells proliferated. Since no integrating vectors were involved and the expression of reprogramming factors was transient, no exogenous factors were expressed in the resultant iPS cells [47] [48] [49] [50] . In the method of reprogramming proteins, reprogramming proteins were fused with cell-penetrating peptides, and these cell-penetrating peptides allowed reprogramming proteins to enter into cells [53, 54] . Since no DNA was directly applied to cells, there is no risk of insertion mutation. Yet, these methods are all associated with dramatically reduced efficiency of iPS cell generation. Moreover, iPS cells derived with adenoviruses tended to become tetraploid for unknown reason [47] . With multiple transfections of non-viral expression vectors, some iPS cell lines had plasmid DNA integration [49] . The fourth strategy is to use different types of donor cells. iPS cells have been derived from many cell types, such as embryonic fibroblast, adult fibroblast, adult hepatocytes and gastric epithelial cells. It has been shown that iPS cell F1 progeny mice with the stomach cell or hepatocyte origin have lower tumor formation rate and lower death rate than those of the F1 mice derived from MEForigin iPS cells [57] . However, it is unclear whether the lower tumor formation rate with iPS cells derived from hepatocytes and gastric epithelial cells was simply due to lower copy number of viral insertion sites or inherent to the donor cells [57] . Thus, it needs further investigation to elucidate whether different types of donor somatic cells can affect the risk for tumor formation.
Preventing Insertion Mutation in iPS Cells
In addition to the tumorigenicity of iPS cells, retrovirus and lentivirus mediating the expression of reprogramming factors also have safety issues. Both retrovirus and lentivirus insert viral DNA together with exogenous genes into genomic DNA, and might cause insertion mutation. To ensure the safety of iPS cells in therapeutic application, the chance of insertion mutation should be minimized. One approach is to use less reprogramming factors. iPS cells have been derived from adult mouse neural stem cells with Oct4 and Klf4, or even just Oct4 alone [58] [59] [60] . Mesenchymal stem cells could be reprogrammed into iPS cells by Oct4 [61] . Oct4 and Nanog together are sufficient to reprogram somatic cells into iPS cells [62] . Alternatively, a single viral vector could express all four reprogramming factors, through the combination of 2A peptide sequence and IRES technology [63] [64] [65] [66] . Thus, the number of integration sites can be minimized. In addition, small molecules could replace some reprogramming factors, hence reducing the possibility of insertion mutation. With an inhibitor of the G9a histone methyltransferase, BIX-01294, iPS cells were established with Sox2, Klf4 and c-Myc, but not Oct4 [67] . BIX-01294 and BayK8644 (a L-channel calcium agonist) allow reprogramming MEF to iPS cells with only Oct4 and Klf4 [68] . Valproic acid (VPA), a histone deacetylase inhibitor, together with two factors Oct4 and Sox2, could efficiently reprogram human fibroblasts to iPS cells [69] . Two distinct transforming growth factor-receptor 1 (Tgfbr1) kinase inhibitors, E-616452 and E-616451, and a Src family kinase inhibitor EI-275 could replace Sox2 in somatic cell reprogramming [70, 71] .
Some of the strategies to reduce the tumorigenicity of iPS cells also decrease the chance of insertion mutation. PB transposon system seamlessly removes exogenous DNA sequences, and restores genomic DNA to the wild type sequence [44, 46] . With non-integrating vector methods, including adenoviruses, Sendai viruses, non-integration episomal vectors and reprogramming proteins, exogenous DNA integration is avoided, hence completely removing the risk for insertion mutation [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . Derivation of iPS cells with reprogramming proteins appears to be the safest method: no genetic material, DNA, is applied during iPS cell generation. Yet, it takes a longer time for iPS colony to appear, and the efficiency of iPS cell derivation is extremely low [53, 54] .
Enhancing Efficiency of iPS Cell Derivation
Except for safety issues, low efficiency in iPS cell generation is a major technical obstacle for the applications of iPS cells, especially when measures are taken to reduce the tumorigenicity and the insertion mutation rate of iPS cells. As mentioned above, omitting c-Myc, adenoviruses, transfection of expression plasmids, episomal vectors, or reprogramming proteins all improve the safety of iPS cells. However, all these methods further reduce the low efficiency of iPS cell derivation [40, 41, 47, 49, 50, 53, 54] . Hence, to achieve higher reprogramming efficiency is a major goal in iPS cell research.
Some studies searched for new reprogramming factors. Knockdown of p53 and over-expression of UTF1 has been shown to promote reprogramming with four Yamanaka factors [72] [73] [74] [75] [76] [77] [78] . Essrb in combination with Oct4 and Sox2 can efficiently reprogram MEF into iPS cells [79] . With mouse ES medium containing soluble Wnt3a, the reprogramming efficiency of Oct4, Sox2, and Klf4 is increased [80, 81] . Interestingly, microRNAs also play important roles in somatic cell reprogramming. Adding at least one microRNA with other reprogramming factor(s) enhances the reprogramming efficiency [82] .
Through screening chemical libraries, small molecules enhancing the efficiency of reprogramming were identified. BIX-01294, an inhibitor of the G9a histone methyltransferase, improved the reprogramming efficiency of Oct4 and Klf4 on neural progenitor cells [67] . Reprogramming efficiency could be increased by using an agent that inhibits histone methylation, especially inhibits H3K9 methylation [83] . DNA methyltransferase and histone deacetylase inhibitors, such as 5-aza-cytidine (AZA) and VPA, also facilitated iPS cell derivation [69, [84] [85] [86] . VPA was required when purified recombinant proteins were used to reprogram MEF cells [53] .
Different types of donor somatic cells might affect the iPS cell derivation rate. It has been shown that the efficiency of iPS cell generation was increase 100-fold when juvenile human primary keratinocytes, instead of human fibroblasts, were used as donor somatic cells. The high reprogramming efficiency allows derivation of iPS cells with keratinocytes isolated from single adult human hair [87, 88] . Alternatively, using dental pulp stem cells as a source of somatic cells, the efficiency of human iPS cell derivation by 3 or 4 factors can be improved dramatically. Similar to keratinocytes from human hair, dental pulp stem cells are easily available. They can be isolated and prepared from extracted wisdom teeth and teeth extracted because of periodontal disease [89] . Adult human adipose stem cells (hASCs) are also a good type of donor somatic cell. They can be easily collected from adult human in large quantities. Thus, there is no need for expansion in cell culture, allowing iPS cell generation directly from freshly isolated hASCs. More importantly, iPS cells can be readily derived from adult hASCs in a feederfree condition, eliminating the risk of cross-species contamination [90] . All these three types of cells, keratinocytes, dental pulp stem cells and hASCs, benefit efficient iPS cell derivation. Meanwhile, acquisition of these cells is simple, without complicated and invasive surgical procedures. Hence, these cells are ideal for the generation of patientspecific iPS cell lines. 
CURRENT & FUTURE DEVELOPMENTS
Although iPS cells were first reported only 4 years ago, the iPS cell field has experienced dramatic progress in such a short period of time. Numerous iPS cell lines have been established in different laboratories all over the world. Various reprogramming methods and strategies were developed to improve the derivation efficiency, quality and safety of iPS cells. Numerous patents in iPS cells are issued every year. Table 2 summarizes important patents in iPS cells. Lights were shed on the nature of iPS cells and somatic reprogramming process. iPS cells have opened a new avenue to generate patient-and disease-specific pluripotent stem cells. These cells can be used for disease models, facilitating studies of disease development in vitro and high throughput drug screening. More importantly, iPS cells hold great promise for regenerative medicine.
Moreover, the success in iPS cell derivation stimulates the thinking whether differentiated somatic cells can be directly reprogrammed into desired cell types, without going through a pluripotent state. Zhou et al. demonstrated that differentiated pancreatic exocrine cells could be converted into -cells in adult mice, by in vivo re-expressing key developmental regulators, Ngn3, Pdx1 and Mafa. The in vivo expression of these regulators was mediated by injection of adenoviruses into the pancreata of living mice, which is a safety risk for human patients. Yet, it proves the feasibility of directing cell reprogramming without fully reversion back to a pluripotent state [91] . Subsequently, it has been shown that fibroblast cells could be converted to functional neurons and cardiomyocytes by different combination of factors [92, 93] . These reprogrammed cells are differentiated cells. Taken out safety issues, they are ready for transplantation, while iPS cells have to differentiate into desired cell types before transplantation. Thus, these directly reprogrammed differentiated cells are alternative cell sources for regenerative medicine.
However, there are also hurdles and challenges to be overcome before applying iPS cells in clinical treatment. First of all, any genetic modification during iPS cell derivation should be avoided. As discussed above, retroviral or lentiviral vectors integrate into genomic DNA and might cause insertion mutations. For clinical application, the risk of insertion mutation should be prevented. Otherwise, the safety of iPS cells should be strictly tested. Second, we have to choose appropriate donor somatic cells for iPS cell generation. Somatic cell origin affects the efficiency of reprogramming. For example, hematopoietic stem cells are more efficiently reprogrammed than terminally differentiated B and T lymphocytes [94] . Ideal somatic cells should be easily obtained without invasive surgery, such as peripheral blood cells, keratinocytes, dental pulp stem cells and hASCs. Large quantities of peripheral blood cells can be harvested by routine venipuncture, overcoming the need for expansion in cell culture. Recent success in reprogramming peripheral blood cells allows them to be used as donor somatic cells for iPS cell generation [48, [95] [96] [97] . In addition to their easy accessibility, keratinocytes, dental pulp stem cells and hASCs appear to be relatively easily reprogrammed to iPS cells [87] [88] [89] [90] . Moreover, iPS cells retain some residual epigenetic memory of donor somatic cells, despite of the extensive epigenetic reprogramming. Epigenetic memory of the original donor cells renders the differentiation potential of iPS cells bias toward certain lineage [98] . Thus, if iPS cells are applied to treat blood disease, blood cells are a better donor cell source than skin cells. Another factor has to be taken into account is different somatic mutation rates in various types of donor cells. To derive clinical-grade iPS cells, it is necessary to start from somatic cells with minimal mutations. Third, methods for highly efficient directed differentiation of iPS cells are needed. For cell replacement therapy, iPS cells have to be differentiated into desired cell type, and then transplanted into patients. Efforts have been made to develop protocols for directed differentiation of iPS cells. iPS cells have been differentiated into neural, cardiovascular and hematopoietic cells [99] [100] [101] . Yet, differentiation efficiencies have to be improved, and methods for purification of desired cells need to be developed. Another major hurdle for therapeutic application of iPS cells is the quality and safety control for iPS cells. iPS cells have been derived with various methods. Which methods generate iPS cell lines with authentic pluripotency, free of tumor risk, and free of insertion mutation? Since somatic cell reprogramming is inefficient and heterogeneous, how do we set the standards to select out iPS cells of high quality?
Despite these challenges, application potential of iPS cells still attracts great attentions and efforts. With continued scientific endeavor, iPS cells will ultimately play a key role of treatment and human health.
